Micrologix begins Phase II trials for acne treatment

Micrologix (TSE:MBI; MGIXF) began a double-blind, 75-patient U.S. Phase II trial of MBI 594AN, a topical product from MBI's Bactolysin cationic peptide series, to treat acne. Patients will be treated ...